Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

The Therapeutic Potential of 4-1BB (CD137) in Cancer

Author(s): Kyung-Ok Nam, Woo J. Kang, Byoung S. Kwon, Sung J. Kim and Hyeon-Woo Lee

Volume 5, Issue 5, 2005

Page: [357 - 363] Pages: 7

DOI: 10.2174/1568009054629681

Price: $65

Abstract

Techniques for modulating immune cells for cancer therapy have been widely studied. One key approach that is being clinically tested is developing tumor-destructive cell-mediated immune responses by regulating co-stimulatory molecules. 4-1BB (CD137), a member of the TNF receptor family, is expressed following activation of T and NK cells. Recently, it has been reported that DCs also express 4-1BB. Crosslinking of 4-1BB provides a potent co-stimulatory signal for lymphocytes via signal transduction pathways that modulate a number of cellular responses. One remarkable response is stimulation of anti-tumor activity in vivo and in vitro. We here review the potential role of 4-1BB in cancer immunotherapy focusing on the cellular and molecular mechanisms involved.

Keywords: cd t cells, cancer, signaling pathways


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy